Results 1 to 10 of about 1,204,710 (358)
T-antigen as a biomarker of progression-free survival in patients with glioblastoma. [PDF]
Ann Clin Transl NeurolAbstractObjectiveGlioblastoma (GBM) is one of the most aggressive brain tumors and often leads to poor outcomes. Studies have indicated that glycan levels are significantly correlated with the pathogenesis and development of cancers. However, whether glycan levels can serve as diagnostic or prognostic biomarkers in GBM remains unclear.MethodsWe ...
Guan L +5 more
europepmc +4 more sources
Comparison of PFS-OS between two treatment methods (surgery and then chemotherapy compared with neoadjuvant and then surgery) in patients with endometrial cancer: a retrospective study [PDF]
Majallah-i Zanān, Māmā̓ī va Nāzā̓ī-i Īrān, 2023 Introduction: Endometrial cancer is one of the common diseases among women, which causes the death of many women in the world every year. The survival of patients and their response to treatment is determined based on clinical conditions and the stage of
Narjes Afrooz +2 more
doaj +1 more source
High-dose-rate endobronchial brachytherapy in the management of advanced lung cancer - comparison according to the presence of lung atelectasis [PDF]
Srpski Arhiv za Celokupno Lekarstvo, 2021 Introduction/Objective. Locally advanced lung cancer is often accompanied by atelectasis of either a part or the entire lung. The aim of this study was to establish the benefits of brachytherapy on the patients’ quality of life, the length of the ...
Bojović Marko +7 more
doaj +1 more source
European Urology Open Science, 2023 The PROpel trial assessed the combination of olaparib + abiraterone acetate (AA) plus prednisone and androgen deprivation therapy (ADT) versus AA plus prednisone and ADT alone as first-line treatment for metastatic castration-resistant prostate cancer ...
Giuseppe Fallara +8 more
doaj +1 more source
Prognostic impact of p16 and p53 gene expressions in stage 1a epithelial ovarian cancer [PDF]
Obstetrics & Gynecology Science, 2020 Objective Epithelial ovarian cancer (EOC) is rarely detected at stage 1a. Most of the patients have a good prognosis and there are limited factors that affect their survival. In the present study, we evaluated the p16 and p53 gene expressions of stage 1a
Emre Günakan +5 more
doaj +1 more source
Progression‐free survival in oncology: Caveat emptor! [PDF]
Basic & Clinical Pharmacology & Toxicology, 2018 AbstractOverall survival (OS) is the undisputed gold standard efficacy end‐point in cancer drug trials. It is with growing concern that we observe how progression‐free survival (PFS) gains ground as surrogate end‐point in its place. PFS has appeal because it is resource‐efficient, but it has severe shortcomings.
Per Damkier +9 more
openaire +3 more sources
An Audit Strategy for Progression-Free Survival [PDF]
Biometrics, 2011 In randomized clinical trials, the use of potentially subjective endpoints has led to frequent use of blinded independent central review (BICR) and event adjudication committees to reduce possible bias in treatment effect estimators based on local evaluations (LE). In oncology trials, progression-free survival (PFS) is one such endpoint.
Suman Bhattacharya +4 more
openaire +3 more sources
Medicina, 2022 Background and Objectives: For stage IIIb–IV ovarian cancer, bevacizumab-containing treatment is considered the standard of care. The purpose of this study was to evaluate the efficacy of bevacizumab in combination with carboplatin and paclitaxel as a ...
Irena Conic +7 more
doaj +1 more source
A nomogram to predict the progression-free survival of clival chordoma [PDF]
Journal of Neurosurgery, 2021 OBJECTIVEChordoma shows poor patient prognosis because of its high recurrence rate. Even though many clinical factors and biomarkers are reported to be associated with prognosis, no prediction model has been applied clinically. Thus, the authors aim to derive and validate a prognostic nomogram to predict progression-free survival (PFS) of chordoma ...
Shuai Wang +7 more
openaire +3 more sources
Surgery, a prognostic marker for progression-free survival? [PDF]
Neuro-Oncology, 2012 Clarke and colleagues1 are to be congratulated for their recently reported retrospective analysis of whether surgery is a prognostic factor for progression-free survival (PFS) based upon 2 datasets of patients (1 each in the pre- and post-temozolomide eras) treated according to the North American Brain Tumor Consortium phase II trials in recurrent ...
Daniel L. Silbergeld +1 more
openaire +3 more sources